Literature DB >> 9447449

Elevated levels of tau and ubiquitin in brain and cerebrospinal fluid in Alzheimer's disease.

K Iqbal1, I Grundke-Iqbal.   

Abstract

Alzheimer's disease (AD) is histopathologically characterized by the presence of numerous neurons with neurofibrillary tangles of paired helical filaments (PHF) in the neocortex, particularly the hippocampus. The major protein subunit of PHF, which also accumulate as neuropil threads and dystrophic neurites of the neuritic (senile) plaques, is the microtubule-associated protein tau. tau in AD brain is abnormally hyperphosphorylated. In addition to hyperphosphorylation, some of the AD tau is also ubiquitinated. The level of tau in AD brain is elevated severalfold, and this increase is in the form of the abnormally phospholylated tau. The levels of conjugated ubiquitin are also increased severalfold in AD brain. The cerebrospinal fluid (CSF) levels of both tau and ubiquitin are elevated in AD. However, some of the normal elderly and non-AD neurological control cases also show elevated levels of these two proteins in the CSF. At present, it is not clear whether the overlap in CSF tau or ubiquitin values between AD and the control groups is due to some unknown heterogeneity of AD, inclusion of presymptomatic AD cases in the control group, or lack of specificity of the CSF elevation of these markers to AD. Thus, until the results of prospective studies on many patients with AD and normal controls become available, the CSF tau and ubiquitin levels can be used only as additional tools in the psychometric and clinical diagnosis of AD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9447449     DOI: 10.1017/s1041610297005024

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN: 1041-6102            Impact factor:   3.878


  10 in total

Review 1.  Biomarkers for Alzheimer disease in cerebrospinal fluid, urine, and blood.

Authors:  Anders Lönneborg
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

2.  PUTATIVE CSF PROTEIN BIOMARKER CANDIDATES FOR AMNESTIC MILD COGNITIVE IMPAIRMENT.

Authors:  Scott E Counts; Elliott J Mufson
Journal:  Transl Neurosci       Date:  2010-03-01       Impact factor: 1.757

Review 3.  Biomarkers for the Early Detection and Progression of Alzheimer's Disease.

Authors:  Scott E Counts; Milos D Ikonomovic; Natosha Mercado; Irving E Vega; Elliott J Mufson
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 4.  Antioxidant therapy in Alzheimer's disease: theory and practice.

Authors:  Gjumrakch Aliev; Mark E Obrenovich; V Prakash Reddy; Justin C Shenk; Paula I Moreira; Akihiko Nunomura; Xiongwei Zhu; Mark A Smith; George Perry
Journal:  Mini Rev Med Chem       Date:  2008-11       Impact factor: 3.862

5.  cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases.

Authors:  Philipp Spitzer; Hans Wolfgang Klafki; Kaj Blennow; Luc Buée; Hermann Esselmann; Sanna-Kaisa Herruka; Connie Jimenez; Peter Klivenyi; Piotr Lewczuk; Juan Manuel Maler; Katrin Markus; Helmut E Meyer; Chris Morris; Thorsten Müller; Markus Otto; Lucilla Parnetti; Hilkka Soininen; Susanna Schraen; Charlotte Teunissen; Laszlo Vecsei; Henrik Zetterberg; Jens Wiltfang
Journal:  Int J Alzheimers Dis       Date:  2010-09-19

6.  Cerebrospinal Fluid proNGF: A Putative Biomarker for Early Alzheimer's Disease.

Authors:  Scott E Counts; Bin He; John G Prout; Bernadeta Michalski; Lucia Farotti; Margaret Fahnestock; Elliott J Mufson
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

Review 7.  The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers.

Authors:  N J Ashton; A Leuzy; T K Karikari; N Mattsson-Carlgren; A Dodich; M Boccardi; J Corre; A Drzezga; A Nordberg; R Ossenkoppele; H Zetterberg; K Blennow; G B Frisoni; V Garibotto; O Hansson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-03-06       Impact factor: 9.236

8.  Mild cognitive impairment: historical development and summary of research.

Authors:  James Golomb; Alan Kluger; Steven H Ferris
Journal:  Dialogues Clin Neurosci       Date:  2004-12       Impact factor: 5.986

Review 9.  The Diagnostic Potential of Amyloidogenic Proteins.

Authors:  Yiyun Jin; Devkee Mahesh Vadukul; Dimitra Gialama; Ying Ge; Rebecca Thrush; Joe Thomas White; Francesco Antonio Aprile
Journal:  Int J Mol Sci       Date:  2021-04-16       Impact factor: 5.923

Review 10.  Blood-based biomarkers for Alzheimer's disease.

Authors:  Antoine Leuzy; Niklas Mattsson-Carlgren; Sebastian Palmqvist; Shorena Janelidze; Jeffrey L Dage; Oskar Hansson
Journal:  EMBO Mol Med       Date:  2021-12-03       Impact factor: 12.137

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.